Publication | Closed Access

Targeting BCL-2 overexpression in various human malignancies through NF-κB inhibition by the proteasome inhibitor bortezomib

Hematological MalignancyTumor BiologyBcl-2 OverexpressionOncologyMedicineMalignant Blood DisorderImmunologyProteasome Inhibitor BortezomibMolecular OncologyAnti-cancer AgentNf-κb InhibitionPharmacologyCancer Research